Duration of therapy of ventilator-associated pneumonia

Current Opinion in Infectious Diseases

Volumn 29, Issue 2, 2016, Pages 218-222

  Dimopoulos, George ^a   Matthaiou, Dimitrios K ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Duration; Gram negative bacilli; Optimization; Treatment; Ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; HUMAN; INTENSIVE CARE; MORBIDITY; MORTALITY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; PNEUMONIA, VENTILATOR-ASSOCIATED; RECURRENT DISEASE; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84960120104     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000245     Document Type: Review

References (28)

1. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
2. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Short-versus longcourse antibacterial therapy for community-acquired pneumonia: a metaanalysis. Drugs 2008;68:1841-1854.
3. Mathai AS, Phillips A, Kaur P, Isaac R. Incidence and attributable costs of ventilator-associated pneumonia (VAP) in a tertiary-level intensive care unit (ICU) in northern India. J Infect Public Health 2015;8:127-135. An up-to-date study regarding the incidence and costs of VAP in the ICU.
4. Kappstein I, Schulgen G, Beyer U, et al. Prolongation of hospital stay and extra costs due to ventilator-associated pneumonia in an intensive care unit. Eur J Clin Microbiol Infect Dis 1992;11:504-508.
5. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003;31:1312-1317.
6. VAP Outcomes Scientific Advisory Group. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115-2121.
7. Ashraf M, Ostrosky-Zeichner L. Ventilator-associated pneumonia: a review. Hosp Pract (1995) 2012;40:93-105.
8. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol 2012;33:250-256.
9. Restrepo MI, Anzueto A, Arroliga AC, et al. Economic burden of ventilatorassociated pneumonia based on total resource utilization. Infect Control Hosp Epidemiol 2010;31:509-515.
10. Karaoglan H, Yalcin AN, Cengiz M, et al. Cost analysis of ventilator-associated pneumonia in Turkish medical-surgical intensive care units. Infez Med 2010;18:248-255.
11. Chastre J, Wolff M, Fagon JY, et al., PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-2598.
12. Fekih Hassen M, Ayed S, Ben Sik Ali H, et al. Duration of antibiotic therapy for ventilator-associated pneumonia: comparison of 7 and 10 days. A pilot study [in French]. Ann Fr Anesth Reanim 2009;28:16-23.
13. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012;16:R218.
14. Capellier G, Mockly H, Charpentier C, et al. Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. PLoS One 2012;7:e41290.
15. Bassetti M, Taramasso L, Giacobbe DR, Pelosi P. Management of ventilatorassociated pneumonia: epidemiology, diagnosis and antimicrobial therapy. Expert Rev Anti Infect Ther 2012;10:585-596.
16. Koulenti D, Lisboa T, Brun-Buisson C, et al., EU-VAP/CAP Study Group. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med 2009;37:2360-2368.
17. Hedrick TL, Smith RL, McElearney ST, et al. Differences in early- and lateonset ventilator-associated pneumonia between surgical and trauma patients in a combined surgical or trauma intensive care unit. J Trauma 2008;64:714-720.
18. Vallés J, Pobo A, García-Esquirol O, et al. Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset. Intensive Care Med 2007;33:1363-1368.
19. Dimopoulos G, Poulakou G, Pneumatikos IA, et al. Short-vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 2013;144:1759-1767.
20. Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015;8:CD007577. A useful update of the comparison between short and long-courseregimens for the treatment of hospital-acquired pneumonia.
21. Combes A, Luyt CE, Fagon JY, et al. Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia. Crit Care Med 2007;35:146-154.
22. Rangel EL, Butler KL, Johannigman JA, et al. Risk factors for relapse of ventilator-associated pneumonia in trauma patients. J Trauma 2009;67:91-95.
23. Dimopoulos G, Matthaiou DK. When the duration of infusion does matter: the case of meropenem and piperacillin. Minerva Anestesiol 2014;80:1258-1260. An interesting editorial investigating various aspects of extended infusion of piperacillin and meropenem and its therapeutic impact.
24. Jean SS, Hsieh TC, Hsu CW, et al. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests. J Microbiol Immunol Infect 2015. [Epub ahead of print] An interesting trial shedding light to the potential role of extended infusion of antibiotics compared to conventional therapeutic regimens for the treatment of VAP.
25. Luyt CE, Gué rin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005;171:48-53.
26. Matthaiou DK, Ntani G, Kontogiorgi M, et al. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 2012;38:940-949.
27. Kollef MH, Hamilton CW, Montgomery AB. Aerosolized antibiotics: do they add to the treatment of pneumonia? Curr Opin Infect Dis 2013;26:538-544.
28. Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med 2015;43:527-533. An interesting study investigating the therapeutic impact of aerosolized colistin combined with intravenous antibiotics in the treatment of VAP.